NTLA Dividend History & Analysis | N/A Yield
NTLA has a dividend yield of N/A and paid N/A per share in the last 12M. Complete payout history, full analyses and peer comparison.
Top Dividend Payers in Biotechnology
| Symbol | Market Cap USD | Dividend Yield TTM | Yield on Cost 5y |
|---|---|---|---|
| ABBV | 390,557 M | 3.34% | 7.54% |
| AMGN | 183,880 M | 3.21% | 5.93% |
| GILD | 176,133 M | 2.79% | 5.63% |
| HLN | 46,623 M | 1.76% | 2.46% |
| BIM | 13,627 M | 0.74% | 0.75% |
| Symbol | Market Cap USD | Growth Rate | Consistency |
|---|---|---|---|
| BTX | 1,425 M | 134% | 95.6% |
| HLN | 46,623 M | 30.1% | 100% |
| AMGN | 183,880 M | 7.84% | 100% |
| BIM | 13,627 M | 9.76% | 96.0% |
| ABBV | 390,557 M | 5.98% | 100% |
Quality Dividend Peers in Biotechnology
3.21% Yield
2.79% Yield
NTLA Dividend History: as of February 2026
No dividends paid yet.NTLA Dividend FAQ
Intellia Therapeutics (NASDAQ:NTLA) is a Cambridge-based, clinical-stage biotech that develops curative in-vivo genome-editing therapies using its CRISPR-Cas9 platform. Its lead candidates are NTLA-2001 (Phase 1 for transthyretin amyloidosis) and NTLA-2002 (Phase 1/2 for hereditary angioedema). The firm also pursues engineered cell-therapy programs, partnering with AvenCell (allogeneic universal CAR-T), Kyverna (CD19 CAR-T for B-cell autoimmune disease), ONK Therapeutics (engineered NK cells) and ReCode Therapeutics (genomic medicines for cystic fibrosis).
What is the Dividend Yield of NTLA?
As of February 2026, NTLA`s dividend yield is %. This is calculated by dividing the trailing 12-month dividend rate (TTM rate) of - by the current share price of 12.36.Does NTLA pay a dividend?
As of February 2026 NTLA does not pay a dividend.How often does NTLA pay dividends?
Over the last 12 months, NTLA has issued dividend payments.NTLA dividend forecast
Based on historical data, the forecasted dividends per share for NTLA for the next 4 payments are between 0 (+0.0%) and 0 (+0.0%).This suggests the dividend will remain relatively stable.
Will NTLA pay dividends in 2026?
The next Ex-Dividend date for Intellia Therapeutics (NTLA) is currently unknown.What is the next Ex-Dividend Date for NTLA?
The next Ex-Dividend date for Intellia Therapeutics (NTLA) is currently unknown. We automatically update the next Ex-Dividend date when it is announced.What is the Dividend Growth of NTLA?
NTLA's average dividend growth rate over the past 5 years is -% per year.
What is the Yield on Cost of NTLA?
NTLA's 5-Year Yield on Cost is -%. If you bought NTLA's shares at 73.92 five years ago, your current annual dividend income (- per share, trailing 12 months) equals -% of your original purchase price.What is the Payout Consistency of NTLA?
NTLA Payout Consistency is 0.0%.
The payout consistency is a proprietary measure of how consistently a company has paid dividends over its lifetime and blends growth rate, number of dividend payments, interruptions or lowering dividends into one number.
Does NTLA have a good Dividend Yield?
NTLA`s % Dividend Yield is considered as unknown.What is the Dividend Payout Ratio of NTLA?
The Dividend Payout Ratio of NTLA is unknown.What is the Dividend Rating of NTLA?
NTLA`s Overall Dividend Rating is (unknown). Ratings surpassing 65% are regarded as acceptable, exceeding 75% are favorable and surpassing 85% are strong.Key Metric Definitions
- Dividend Yield
- Annual dividend per share divided by current share price.
- Payout Ratio
- Percentage of earnings paid as dividends. Below 60% = safe, above 100% = unsustainable.
- Payout FCF
- Percentage of Free Cash Flow paid as dividends. More reliable than Payout Ratio since it measures actual cash.
- Growth Rate (CAGR)
- Compound annual growth rate of dividends over the last 5 years.
- Consistency
- Reliability of dividend payments over lifetime. Penalizes cuts and pauses.
- Yield on Cost
- Your effective yield if you bought 5 years ago. Shows dividend growth impact over time.
- Streak
- Consecutive years of dividend payments. 25+ years = Dividend Aristocrat.
- Dividend Rating
- Proprietary score (0-100) combining yield, growth, safety and consistency.
Last update: 2026-01-28 02:39